Skip to main content

Table 1 Baseline demographics and clinical characteristics

From: Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial

 

12H group

(n = 19)

24H group

(n = 20)

p value

Age, month

25 [2–75]

32 [7–118]

0.196

Men

11 (57.9)

11 (55.0)

1.00

Days of illness at enrollment

5 [4–7]

5 [4–6]

0.915

Risk score

4 [0–7]

1 [0–6]

0.022

Laboratory data

 White blood cell count, 109/L

12.4 ± 3.4

12.4 ± 4.0

0.993

 Neutrophils, %

71.2 ± 13.3

67.2 ± 15.6

0.403

 Platelet count, 1010/L

31.1 ± 7.3

36.2 ± 9.3

0.067

 Albumin, g/L

3.3 ± 0.4

3.5 ± 0.4

0.111

 Creatinine, mg/dL

0.27 ± 0.06

0.27 ± 0.07

0.664

 Aspartate aminotransferase, U/L

99 ± 159

38 ± 21

0.092

 Sodium, mEq/L

133 ± 3

137 ± 3

< 0.01

 C-reactive protein, mg/dL

7.3 ± 3.9

6.4 ± 5.9

0.564

 IgG, mg/dL

624 ± 155

754 ± 167

0.021

  1. Data are median [range], number (percentage), or mean ± SD
  2. IVIG indicates intravenous immunoglobulin
  3. IgG indicates immunoglobulin G
  4. 12H indicates 12 h
  5. 24H indicates 24 h